You are here
Gloria Patricia Cardona-Gomez, Ph.D.
University of Antioquia
Areas of Interest:
Cellular and molecular neurobiology; age related dementias; neurodegeneration; neuroprotection; brain repair; brain plasticity; neuronal morphology; pharmacological agents; animal models; animal behavioural testing.
Biography & Research:
Gloria Patricia Cardona-Gomez is B.Sc, Ph.D., Full professor and Senior researcher, at the Faculty of Medicine, University of Antioquia (UdeA). Coordinator of the Cellular and Molecular Neurobiology area in the Neuroscience Group of Antioquia (GNA, UdeA). She is corresponding member of the Colombian Academy of physical, exacts and natural Sciences (ACCEFYN) (2016- ) and elected member of Executive Committee of FALAN-IBROLARC (2018-2020). She has a wide scientific experience in neuroprotection, mainly considering the convergence between cerebral plasticity and survival signalling. She did her doctoral studies in the Cajal Institute, CSIC in Madrid, Spain working in neuroplasticity and neuroprotection under the scientific advise of Dr. Luis Miguel Garcia-Segura. Also, She did her postdoctoral training in Brain plasticity at the Cajal Institute in collaboration with the “Severo Ochoa” Molecular Biology Center, UAM-CSIC. After, she came back to Colombia, through a R21/R01 Fogarty/NIA, NIH funding as co-PI, took training in Gene therapy using RNA interference as treatment for neurodegeneration using AD transgenic animal models in the UCSB and in the University of Iowa, USA; applying this new technology in her lab in Colombia. Through her international collaboration with those institutions, she assembled infrastructure for developing competitive basic neuroscience and to strengthen academic networks in Colombia . Concomitantly, she has developed research in pharmacological therapies using bioactive substances from plants in cognitive impairment in AD and cerebral ischemia models and its potential in translational medicine. Other current perspectives are lipidomic as neuropathological hallmarks and biomarkers of the vascular cognitive impairment and dementia (VCID) progression.